Thursday, March 16, 2017 4:30:03 PM
'Pursuant to the Collaboration Agreement, we are responsible for completing the three ENCORE trials and the POLT-HCV-SVR trial described above . Prior to Novartis’ exercise of the option, Novartis will reimburse us for any costs of the se four Phase 2 b t rials that exceed an agreed upon budget or we will credit any amount under budget to Novartis’ future costs for the four Phase 2 b t rials. If Novartis exercises its option, we will share the costs of the se four Phase 2 b trials equally with Novartis after the effective date of the license grant under the Collaboration Agreem ent . Novartis will also be responsible for 100% of certain expenses for required registration-supportive nonclinical activities . Novartis will be responsible for the development of emricasan beyond the four Phase 2 b trials described above , including the Ph ase 3 development of emricasan single agent products and all development for emricasan combination products , and Novartis has agreed to use commercially reasonable efforts to develop and commercialize emricasan products , if the option is exercised . A joint steering committee comprised of representatives from our company and Novartis will oversee the collaboration, development and commercialization of emricasan products.'
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM